Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.1300 (0.79%) ($5.1300 - $5.1300) on Thu. Jul. 15, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.57% (three month average) | RSI | 45 | Latest Price | $5.1300(0.79%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.8% a day on average for past five trading days. | Weekly Trend | ADMS declines -0.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XLC(20%) VT(15%) SIL(43%) SMH(42%) SKYY(31%) | Factors Impacting ADMS price | ADMS will decline at least -1.785% in a week (0% probabilities). IWD(-3%) KWEB(6%) JETS(-5%) IFRA(-23%) IWN(0%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.785% (StdDev 3.57%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.29 | 5 Day Moving Average | $5.2(-1.35%) | 10 Day Moving Average | $5.33(-3.75%) | 20 Day Moving Average | $5.29(-3.02%) | To recent high | -12.6% | To recent low | 2.4% | Market Cap | $145m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |